Is There a Generic Semaglutide? What to Know in 2026

If you have been searching for a generic version of your GLP-1 medication to bring the cost down, here is the honest answer: as of 2026, there is no FDA-approved generic semaglutide or tirzepatide available in the US. These medications are still protected by patent, so a generic copy is not on the market yet. Compounded medication is sometimes confused with a generic, but it is not the same thing.

The short answer

There is no FDA-approved generic semaglutide and no FDA-approved generic tirzepatide in the United States right now. Both molecules remain under patent and exclusivity protection, which legally prevents any other manufacturer from selling an approved generic copy.

You may have seen the word “generic” used loosely online, sometimes attached to lower-cost telehealth offers. That usage is inaccurate and, in marketing, a known compliance problem. What those programs typically offer is compounded medication, which is a different category with a different regulatory status. The rest of this page explains the difference clearly so you can make a decision based on what is actually true.

Generic vs brand vs compounded: what the difference actually is

These three terms get used interchangeably, but they mean very different things. Getting the distinction right matters, because it affects what you are actually paying for and how it has been reviewed.

Brand-name medication is the original, FDA-approved product made by the company that developed it. It went through full FDA review for safety, efficacy, and quality, and it is sold under a registered trademark. Brand-name semaglutide and brand-name tirzepatide fall into this category.

A generic After the original patent and exclusivity protections expire, other manufacturers can apply to make a generic through the FDA’s generic drug approval pathway (the abbreviated new drug application, or ANDA, process). To be approved, a generic must be shown to be bioequivalent to the brand and is held to FDA quality standards. There is currently no generic semaglutide or tirzepatide because that pathway is not open while the molecules are still under patent.

A compounded medication is prepared by a state-licensed compounding pharmacy, typically from active pharmaceutical ingredients, based on a prescription written by a licensed provider. Compounded medication is not FDA-approved. It has not been independently evaluated by the FDA for safety, efficacy, or quality, and it may differ from the brand-name product in formulation, potency, and purity. A compounded medication is not a generic, and it is not “the same as” or “equivalent to” a brand-name product. It is its own distinct category.

The simplest way to hold it in your head: a generic is an FDA-reviewed copy that only exists after patents expire. Compounded medication is something a licensed pharmacy prepares now, under different rules, without FDA approval.

Why there is no generic yet

The reason comes down to patent and exclusivity protections. When a company develops a new medication, it receives a period of legal protection that prevents competitors from making approved copies. That protection is what allows no FDA-approved generic to exist for semaglutide or tirzepatide today.

Until those protections expire, the FDA cannot approve a generic through the ANDA pathway, so no legitimate generic can be sold. When that window closes is not something we can tell you with confidence. The timing has not been publicly announced, and you should be cautious of any source that claims to know an exact date. Anyone promising a specific generic launch date is guessing.

So if you are waiting for a cheaper FDA-approved generic to appear, the accurate picture is that it is not available now and the timeline is uncertain. That leaves a practical question: what are your legitimate lower-cost options today?

What this means if you are looking for a lower-cost option

You came here looking to lower your cost, and that goal is completely reasonable. Brand-name GLP-1 medications can run roughly $900 to $1,500 per month without insurance, which puts them out of reach for many people. A generic would help, but it does not exist yet.

The legitimate lower-cost cash-pay route available today is a compounded GLP-1 program through a licensed provider. Here is how that works in plain terms. You complete an online intake covering your health history. An independent, licensed provider reviews it and determines whether a GLP-1 medication is appropriate for you. If it is, a state-licensed US compounding pharmacy prepares your medication and ships it to your door, and your provider monitors your progress over time.

This is not a generic, and we want to be precise about that. Compounded medication is not FDA-approved and has not been evaluated by the FDA for safety, efficacy, or quality. The reason it can cost less than the brand is the compounding pharmacy model, not FDA review or generic status. The right way to think about it is as a separate, legitimate option you can access now, prescribed and overseen by a licensed provider, rather than a budget version of the brand.

If you want to read more about the regulatory side, our overview of compounded GLP-1 medications covers the framework, and our page on compounded semaglutide safety explains how to tell a legitimate provider from an unsafe online seller. For a broader cost comparison, see GLP-1 medication without insurance and the medication pricing overview.

What it costs

Transformation Health offers all-inclusive pricing. One monthly payment covers your medication, lab work at Quest or Labcorp, provider care, and medical weight loss coaching. There are no separate bills and no hidden fees, and you can cancel anytime. FSA and HSA cards are accepted.

For a detailed breakdown of what a compounded program runs each month, see our guide to compounded semaglutide cost.

Important disclosures

There is no FDA-approved generic semaglutide or tirzepatide available in the US as of 2026. Both molecules remain under patent and exclusivity protection. Compounded medications are not generics and are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from brand-name products in formulation, potency, and purity.

Eligibility for a GLP-1 program generally requires a BMI of 30 or higher, or 27 or higher with a weight-related condition. Not all patients will qualify. All prescriptions require evaluation by an independent, licensed provider, and final prescribing decisions are made by that provider. Residents of Arkansas, Washington D.C., Delaware, Mississippi, New Mexico, Rhode Island, and West Virginia are required by state law to complete a live video consultation before a prescription can be written.

This page is for general educational purposes and does not predict when any generic may become available. We do not provide specific patent-expiry or launch dates, because that timing is uncertain and has not been publicly announced. Results vary by individual.